And as mentioned at the BIOX conference, by another immunotherapy company, a large factor to investment interest is when big pharma starts poking around.
paraphrased: Big pharma typically won't come in until there is phase 2 data.
Some may think interim data is enough...
So, Phase 2 is when the larger investors start climbing on board.
Where are we again?
Not many stops between now and then.
And as mentioned at the BIOX conference, by another...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.5¢ |
Change
0.005(1.25%) |
Mkt cap ! $588.3M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 40.5¢ | 39.8¢ | $2.431M | 6.045M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6880 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.5¢ | 85353 | 3 |
View Market Depth
| Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |